文献速递甲状腺疾病

免疫功能低下与免疫功能正常的分化型甲状腺癌患者结局相当

Comparable Outcomes of Differentiated Thyroid Cancer in Immunocompromised Versus Immunocompetent Patients.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本研究在纪念斯隆-凯特琳癌症中心比较了1987至2020年间免疫功能低下与倾向性匹配的免疫功能正常的分化型甲状腺癌(DTC)成人患者的临床特征和结局。在8534例DTC患者中,130例(1.5%)存在免疫缺陷,经5:1倾向性匹配后纳入650例免疫功能正常者对照。

要点

  • DTC在免疫缺陷患者中总体预后良好,与免疫正常者相当。

核心结论

  • 免疫功能低下与免疫功能正常的DTC患者预后相当。

研究设计与样本

  • 回顾性研究,比较1987至2020年纪念斯隆-凯特琳癌症中心的成人DTC患者,免疫缺陷组与倾向性匹配的免疫正常对照组按5:1比例纳入。

主要发现

  • 8534例DTC患者中130例(1.5%)为免疫缺陷,匹配后纳入650例免疫正常对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Differentiated thyroid cancer (DTC) is generally a highly treatable malignancy with low mortality and a favorable prognosis. However, the impact of immunodeficiency on DTC outcomes remains poorly understood, with research largely limited to organ transplant recipients. This study aimed to address this gap by comparing the clinical characteristics and outcomes of DTC in immunocompromised patients with a propensity-matched cohort of immunocompetent individuals. METHODS: The study compared adult patients with DTC and preexisting immunodeficiencies treated at Memorial Sloan-Kettering Cancer Center between 1987 and 2020 to a propensity-matched control group of immunocompetent patients, with a 5:1 comparison ratio. Data on demographics, disease characteristics, and outcomes were analyzed. RESULTS: Among 8534 DTC patients, 130 (1.5%) were immunocompromised. After propensity score matching, 650 immunocompetent patients were included for comparison. Recurrence-free survival did not differ significantly between groups (P = .94), with recurrence rates remaining below 10% in both cohorts over 180 months. At 10 years, disease-specific survival was also similar (P = .34), with rates of 100% for immunocompromised and 98% for immunocompetent patients. CONCLUSION: DTC has a comparable prognosis in immunocompetent and immunocompromised patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ritter A, Eagan A, Levyn H, et al. Comparable Outcomes of Differentiated Thyroid Cancer in Immunocompromised Versus Immunocompetent Patients. J Clin Endocrinol Metab. 2026. PMID: 41054817. doi:10.1210/clinem/dgaf550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。